Nanohale AG (FYB) | Finanzwire

BRIEF

published on 12/11/2024 at 16:31, 10 days ago

Formycon AG Maintains Strong Growth Prospects Amidst Challenging Market Conditions

FDA Approval Revenue Decline Formycon AG Biosimilars Stelara Launch
PRESS RELEASE

published on 12/11/2024 at 16:26, 10 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research publishes update on Formycon AG with BUY rating and EUR 82.00 price target, highlighting decline in revenue and upcoming biosimilar launches

First Berlin Equity Research BUY Rating Formycon AG EUR 82.00 Price Target Biosimilar Launches
BRIEF

published on 12/09/2024 at 06:35, 12 days 10 hours ago

MS Pharma to Commercialize FYB202 in MENA

MENA Region Formycon AG Biosimilars MS Pharma FYB202
PRESS RELEASE

published on 12/09/2024 at 06:30, 12 days 10 hours ago

MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region
Formycon AG and MS Pharma sign licensing and supply agreement for the commercialization of FYB202/ustekinumab biosimilar in MENA region, expanding patient access to vital treatments

MENA Region Formycon AG MS Pharma FYB202 Ustekinumab
BRIEF

published on 12/05/2024 at 13:00, 16 days 3 hours ago

Formycon Joins the SDAX of the German Stock Exchange

Market Strategy Biosimilars SDAX Formycon German Stock Exchange
PRESS RELEASE

published on 12/05/2024 at 12:55, 16 days 3 hours ago

Formycon joins the SDAX of the German Stock Exchange
Formycon AG joins the SDAX of the German Stock Exchange, enhancing share attractiveness and visibility in the capital market. Key milestone in the company's growth strategy

Formycon AG Biosimilars Capital Market SDAX German Stock Exchange
BRIEF

published on 11/28/2024 at 06:35, 23 days 10 hours ago

Formycon Reports Continued Growth in 2024 Nine-Month Results

Financial Results Market Position FDA Approval Biosimilars Strategic Growth
PRESS RELEASE

published on 11/28/2024 at 06:30, 23 days 10 hours ago

Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes
Formycon reports nine-month results for 2024 with operational successes and growth trajectory, including product approvals and new biosimilar candidates

Biosimilars Growth Trajectory Formycon Nine-month Results Operational Successes
BRIEF

published on 11/19/2024 at 06:35, 1 month 2 days ago

Formycon Announces Earnings Call and Conference Participation

Financial Results Investor Conference Frankfurt Stock Exchange Formycon AG Earnings Call
PRESS RELEASE

published on 11/19/2024 at 06:30, 1 month 2 days ago

Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
Formycon AG invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences. Management Board to discuss key financial figures and recent uplisting to the Prime Standard of Frankfurt Stock Exchange

Investor Conferences Formycon AG Biosimilars Earnings Call Nine-month Results

Published on 12/21/2024 at 01:30, 15 hours 20 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 15 hours 20 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 16 hours 45 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 16 hours 50 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 17 hours 20 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 15 hours 59 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 16 hours 5 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 21 hours 39 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 21 hours 54 minutes ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 22 hours 50 minutes ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 4 hours 32 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 22 hours 50 minutes ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 22 hours 55 minutes ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 2 hours ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 1 day 22 hours ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE

News